IP Library Granted Patent US 9,314,456
Granted Patent B2
US 9,314,456 · App. 14/616,006 · Granted Apr 19, 2016

Antibacterial compounds

Inventors: Francis Xavier Wilson (Abingdon, GB); Peter David Johnson (Abingdon, GB); Richard Vickers (Abingdon, GB); Richard Storer (Abingdon, GB); Graham Michael Wynne (Abingdon, GB); Alan Geoffrey Roach (Abingdon, GB); Olivier De Moor (Abingdon, GB); Colin Richard Dorgan (Abingdon, GB); Paul James Davis (Abingdon, GB)
Assignee: SUMMIT THERAPEUTICS PLC
A61K31/444C07D235/18C07D401/14
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,314,456
App. No.
14/616,006
Granted
Apr 19, 2016
Kind
B2
Abstract

Disclosed are compounds of formula (I): which are of use in the treatment of bacterial diseases and infections, to compositions containing those compounds and to methods of treating bacterial diseases and infections using the compounds. In particular, the compounds are useful for the treatment of infection with, and diseases caused by, Clostridium difficile.

Claims (3)

1. A pharmaceutical composition comprising: a hydrate of the compound 2,2′-di(pyridin-4-yl)-1H, 1′H-5,5′-bibenzo[d]imidazole and a pharmaceutically acceptable excipient.

2. A method of treating Clostridium difficile -associated disease (CDAD) in a subject in need thereof, the CDAD selected from the group consisting of diarrhoea caused by Clostridium difficile , bloating caused by Clostridium difficile , flu-like symptoms caused by Clostridium difficile , fever caused by Clostridium difficile , appetite loss caused by Clostridium difficile , abdominal pain caused by Clostridium difficile , nausea caused by Clostridium difficile , dehydration caused by Clostridium difficile , colitis caused by Clostridium difficile and pseudomembraneous colitis caused by Clostridium difficile , which method comprises administering to said subject an effective amount of a hydrate of the compound 2,2′-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole.

3. A composition comprising a hydrate of the compound 2,2′-di(pyridin-4-yl)-1H,1′H-5,5′-bibenzo[d]imidazole.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2018
From: SUMMIT THERAPEUTICS PLC
To: SUMMIT (OXFORD) LIMITED
Reel/Frame 044859/0983 →
CHANGE OF NAME Recorded Oct 6, 2015
From: SUMMIT CORPORATION PLC
To: SUMMIT THERAPEUTICS PLC
Reel/Frame 036851/0371 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 16, 2015
From: DAVIS, PAUL JAMES; DE MOOR, OLIVIER; DORGAN, COLIN RICHARD; JOHNSON, PETER DAVID; ROACH, ALAN GEOFFREY; STORER, RICHARD; VICKERS, RICHARD JOHN; WILSON, FRANCIS XAVIER; WYNNE, GRAHAM MICHAEL
To: SUMMIT CORPORATION PLC
Reel/Frame 036575/0561 →
Priority Claims (1)
GB 0821913.1 · Dec 2, 2008 · national
Continuity (2)
Continuation 13131469
Related Publication 20150150861A1 · Jun 4, 2015